Takeda Forms Global Strategic Alliance with Innovent Biologics to Enhance Oncology Pipeline with Advanced Investigational Treatments for Solid Tumors

Collaboration Agreement: Takeda has entered a licensing and collaboration agreement with Innovent Biologics for the development and commercialization of two late-stage oncology medicines, IBI363 and IBI343, outside of Greater China, with Takeda leading efforts in the U.S. and holding global manufacturing rights.

Medicinal Potential: IBI363, a bispecific antibody fusion protein, and IBI343, an antibody-drug conjugate, are both showing promising clinical activity in treating various solid tumors, including non-small cell lung cancer and pancreatic cancer, with Fast Track designations from the FDA for both therapies.